nature portfolio

| Corresponding author(s): | Wright |
|----------------------------|------------|
| Last updated by author(s): | 2024-30-01 |

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

| _ | | | | | |
|---|----|-----|-----|---|--------|
| 5 | tа | ıtı | ist | ш | \sim |

| For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. | |
|---|-----|
| n/a Confirmed | |
| The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement | |
| A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly | |
| The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. | |
| A description of all covariates tested | |
| A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons | |
| A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) | nt) |
| For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable. | |
| For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings | |
| For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes | |
| Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated | |
| Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. | |
| Software and code | |
| Policy information about <u>availability of computer code</u> | |
| Data collection Data were provided by LIK Biobank | |

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

STATA v16.0 was used to perform logistic and linear regressions

Data are available from the UK Biobank under managed access,see https://biobank.ndph.ox.ac.uk/showcase/; DDG2P available from https://www.ebi.ac.uk/gene2phenotype/

| Human | research | partici | pants |
|----------|-------------|---------|--------|
| Hulliali | 1 C3Cal Cl1 | partici | pariti |

| Policy information | about <u>studies ir</u> | nvolving human research participants and Sex and Gender in Research. | | | |
|--|-------------------------|---|--|--|--|
| Reporting on sex | and gender | Information on sex is available from UK Biobank, but we did not evaluate this aspect specifically other than to control for it in our analyses. | | | |
| Population characteristics | | We have outlined the population characteristics, and referenced other publications that outline the UK Biobank population in more detail; age at recruitment 40-70 | | | |
| Recruitment | | Recruitment was performed by UK Biobank | | | |
| Ethics oversight | | Ethical approval was provided by UK Biobank | | | |
| Note that full informa | ation on the appr | oval of the study protocol must also be provided in the manuscript. | | | |
| Field-spe | ecific re | porting | | | |
| Please select the o | ne below that is | s the best fit for your research. If you are not sure, read the appropriate sections before making your selection. | | | |
| Life sciences | В | ehavioural & social sciences | | | |
| For a reference copy of t | the document with | all sections, see nature.com/documents/nr-reporting-summary-flat.pdf | | | |
| | | | | | |
| Lite scier | nces stu | udy design | | | |
| All studies must dis | sclose on these | points even when the disclosure is negative. | | | |
| Sample size | | tated in the manuscript was everyone in UK Biobank with exome sequence data and European ancestry defined genetically (as manuscript); specifically, 419,854 individuals were included. | | | |
| Data exclusions | No individuals v | were excluded from the analysis, based on the criteria above. | | | |
| Replication | | ne largest available dataset in which to perform this research and thus replication was not attempted elsewhere. Since we are w disease associations, we do not consider this to be a problem. | | | |
| Randomization | Not relevant to | the study design | | | |
| Blinding | Not relevant to | the study design | | | |
| | | | | | |
| D | - C | | | | |
| <u> </u> | - | pecific materials, systems and methods | | | |
| | | about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. | | | |
| Materials & exp | norimontal s | ystems Methods | | | |
| | | n/a Involved in the study | | | |
| n/a Involved in the study | | | | | |
| Eukaryotic | cell lines | Flow cytometry | | | |
| Palaeontology and archaeology MRI-based neuroimaging | | | | | |
| Animals and other organisms | | | | | |
| Clinical dat | Clinical data | | | | |
| Dual use re | esearch of concer | n | | | |